-
MEDIMABBIO
-
DISCOVER
NEXT GENERATION IMMUNOTHERAPY
FOR CANCER
-
MEDIMABBIO
-
DISCOVERNEXT GENERATION IMMUNOTHERAPY
FOR CANCER
-
MEDIMABBIO
-
DISCOVERNEXT GENERATION IMMUNOTHERAPY
FOR CANCER
SCROLL DOWN
About Us
MediMabBio is a ground-breaking biotherapeutic company focusing on the generation of novel immunotherapies for the treatment of cancer.
Our discovery platform uses advances in systems biology combined with sophisticated immunological solutions to identify significantly improved first-in-class immuno-oncology drugs that can actively target a range of advanced and solid tumors.
The company has developed pipelines of highly promising novel drugs that aim to overcome the current limitations of cancer immunotherapy.
For this purpose, MediMabBio has established collaborations with core partners of academic, R&D institutions and clinical groups in US, UK, Germany, China and Korea.
Research
MediMabBio antibody discovery I-O platform brings the advantages of rational drug design tothe large molecule therapeutic development. Following are the areas of our research:
- Integration of high-quality computational datasets and structural modelling for precise targeting
- De novo design and selection of antibody leads with optimized functionality, safety and developability criteria
- Establishment and use of cancer patients-derived HMNC/TIL screening system for bringing better therapeutic development plans
- Development of neokine-tethered-antibody fusion platform for targeting difficult-to-treat-cancers
Pipeline
MMB pipeline addresses significant medically unmet needs in immuno-oncology by directlytargeting T cells, immune checkpoints and tumor micro-environment.
| Category | Program | Therapeutic Indication | Development stage | |||||
|---|---|---|---|---|---|---|---|---|
| Target Discovery | Hit Optimization | Lead Optimization | Pre-clinical | IND | Clinical | |||
| Immune Checkpoint Antibody | MMB-101 | Immuno Oncology | ||||||
| MMB-102 | Immuno Oncology | |||||||
| MMB-103 | Immuno Oncology | |||||||
| Immuno-cytokine | MMB-201 | Immuno Oncology | ||||||
| Program | Therapeutic Indication | Development stage | ||||
|---|---|---|---|---|---|---|
| Discovery | Development | Pre-/Clinical | ||||
| MMB-101 | Immuno Oncology | |||||
| MMB-102 | Immuno Oncology | |||||
| MMB-103 | Immuno Oncology | |||||
| MMB-201 | Immuno Oncology | |||||
| Program | Development stage | ||
|---|---|---|---|
| Discovery | Development | Pre-/Clinical | |
| MMB-101 | |||
| MMB-102 | |||
| MMB-103 | |||
| MMB201 | |||
Management
-
Jennifer Yuhoi Kang, Ph.D Founder & Co-CEOEXPERIENCE- Samsung Bioepis
- Samsung Advanced Institute of Technology
- Harvard Medical School
- University of Oxford
therapy, Vaccine development -
Hongseok Jo, Ph.D Founder & Co-CEOEXPERIENCE- Samsung Bioepis
- Samsung Advanced Institute of Technology
- KAIST
Oncology, Neurological disorder
MEDIMABBIONews
-
MediMabBio has made a contract with a leading global CDMO Thermo Fisher Scientific to manufacture drug substances and drug products for clinical trials.
MediMabBio has made a contract with a leading global CDMO Thermo Fisher Scientific to take the first step towards clinical trial approval with its first pipeline, MMB101. The MMB101 product is a monoclonal antibody that targets immune checkpoints. Through the new Quick to Clinic Solution of Thermo Fisher Scientific, MediMabBio plans to accelerate cell line and process development. Also, both companies will collaborate to manufacture drug substances and drug products for clinical trials.
-
MediMabBio has made a collaboration deal with University Hospitals of Birmingham, UK
MediMabBio has launched the first project to test its main pipelines (i.e. MMB101, MMB102) globally by partnering with University Hospitals of Birmingham, which have conducted the largest number of clinical trials of liver-related diseases in UK. MediMabBio plans to expand the collaboration with the University Hospitals in areas of autoimmune diseases and NASH treatment. 2021.06.28. -
MMB has successfully completed a Series-A fundraising with 18 million USD.
MMB has successfully completed a Series-A fundraising with 18 million USD in February 2021. 7 investors have participated with current investors following-on. There are 15 people in Korea and UK offices currently with more than 90 percent of them holding Masters and doctoral degrees. Two of their pipelines, MMB 101 and MMB 102, are expected to enter into pre-clinical study at the end of this year, and one of the pipelines, MMB 201, at the beginning of next year. 2021.02.15.
Contact
Korea
- MediMabBio Inc.
- #721, 54, Changeop-ro, Sujeong-gu, Seongnam-si,
Gyeonggi-do, Republic of Korea, 13449 - info@medimabbio.com
- 82-(0)31-623-2100
- 82-(0)31-751-2101
United Kingdom
- MediMab Biotherapeutics Ltd.
- BioEscalator, the Innovation Building, the Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7FZ United Kingdom
- infouk@medimabbio.com
- 44-(0)20-7460-7899
